Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isosulfan blue is a triarylmethane diagnostic dye used for lymphatic mapping and sentinel lymph node (SLN) identification, particularly in breast cancer and melanoma. Following subcutaneous or intraparenchymal injection, the dye binds to interstitial albumin and is selectively transported via the lymphatic system, staining lymphatic vessels and nodes a distinct blue color. This visualization enables surgeons to identify the primary draining nodes for biopsy, facilitating accurate cancer staging while reducing the morbidity associated with complete lymph node dissection. While effective, its use is associated with a risk of hypersensitivity reactions, including life-threatening anaphylaxis in approximately 1% of patients, and it can cause factitious oxygen desaturation readings on pulse oximetry.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isosulfan blue.